Status: Recruiting
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AHS Cancer Control AlbertaUpdated: Jun 27, 2025Locations: 1
Eligibility criteria
Patients must be 18 years of age or older. [+13]
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular... [+3]